PreveCeutical Medical Inc (PRVCF)
OTHER OTC:PRVCF

PreveCeutical Medical (PRVCF) Income Statement

37 Followers

PreveCeutical Medical Income Statement

Last quarter (Q4 2023), PreveCeutical Medical's total revenue was C$―, a decrease of ― from the same quarter last year. In Q4, PreveCeutical Medical's net income was C$-235.40K. See PreveCeutical Medical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
-----C$ 3.03K
Cost of Revenue
-----C$ 779.00
Gross Profit
-----C$ 2.25K
Operating Expense
C$ 810.49KC$ 963.12KC$ 1.06MC$ 897.85KC$ 2.16MC$ 3.57M
Operating Income
C$ -810.49KC$ -963.12KC$ -1.06MC$ -897.85KC$ -2.16MC$ -3.57M
Net Non Operating Interest Income Expense
C$ -317.11KC$ -309.53KC$ -206.82KC$ 466.90KC$ 640.04KC$ -578.69K
Other Income Expense
--C$ 175.50KC$ -382.30KC$ -1.00MC$ 564.58K
Pretax Income
C$ -1.13MC$ -1.27MC$ -1.48MC$ -1.75MC$ -3.81MC$ -3.59M
Tax Provision
---C$ -20.48KC$ -6.15KC$ -7.88K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
C$ -1.13MC$ -1.27MC$ -1.48MC$ -1.73MC$ -3.80MC$ -3.58M
Basic EPS
----C$ -0.01C$ >-0.01
Diluted EPS
----C$ -0.01C$ >-0.01
Basic Average Shares
C$ 2.14BC$ 535.30MC$ 521.79MC$ 507.95MC$ 455.87MC$ 395.75M
Diluted Average Shares
C$ 2.14BC$ 535.30MC$ 511.70MC$ 507.95MC$ 455.87MC$ 395.75M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
-----C$ -65.33K
Total Expenses
C$ 810.49KC$ 963.12KC$ 1.06M--C$ 3.58M
Interest Expense
-----C$ 578.69K
Net Income From Continuing And Discontinued Operation
C$ -1.13MC$ -1.27MC$ -1.48MC$ -1.73MC$ -3.80MC$ -3.58M
Normalized Income
C$ -889.61KC$ -936.74KC$ -1.05MC$ -1.60MC$ -2.52MC$ -4.08M
EBIT
C$ -811.57KC$ -964.94KC$ -1.27MC$ -1.28MC$ -3.17MC$ -3.01M
EBITDA
C$ -801.71KC$ -955.09KC$ -1.26MC$ -1.28MC$ -3.09MC$ -2.83M
Currency in CAD

PreveCeutical Medical Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis